Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 3

Conditions

Multiple Myeloma 420Lymphoma, Large B-Cell, Diffuse 93Leukemia, Lymphocytic, Chronic, B-Cell 88Lymphoma, Follicular 79Recurrence 68Lymphoma 60Neoplasms, Plasma Cell 57Lymphoma, Mantle-Cell 56Lymphoma, B-Cell, Marginal Zone 47Lymphoma, Non-Hodgkin 46Leukemia, Myeloid, Acute 34Leukemia 32Lymphoma, B-Cell 24Neoplasms 23Myelodysplastic Syndromes 23Waldenstrom Macroglobulinemia 18Hodgkin Disease 18Smoldering Multiple Myeloma 17Lymphoma, T-Cell, Peripheral 16Burkitt Lymphoma 14Hematologic Diseases 13Lymphoma, T-Cell, Cutaneous 12Lymphoma, T-Cell 12Prostatic Neoplasms 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Sezary Syndrome 10Mycosis Fungoides 10Lymphoma, Large-Cell, Anaplastic 9Leukemia, Myelomonocytic, Chronic 9Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8

Interventions

ibrutinib 8fludarabine 8fludarabine phosphate 7Cyclophosphamide 7Busulfan 6Rituximab 5blinatumomab 4Whole-Body Irradiation 4Tacrolimus 4Peripheral Blood Stem Cell Transplantation 4Mycophenolic Acid 4Melphalan 4Methotrexate 3Mesna 3Lenalidomide 3Bendamustine Hydrochloride 3thymoglobulin 2pirtobrutinib 2Vincristine 2Patient Reported Outcome Measures 2Doxorubicin 2Bone Marrow Transplantation 2Biopsy 2Behavior Therapy 2Alemtuzumab 2venetoclax 1tozasertib 1sargramostim 1romiplostim 1pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Leukemia, Lymphoid × Lenalidomide × Clear all
NCT01754857 2023-06-27

Bendamustine and Rituximab Induction Therapy and Maintenance Rituximab and Lenalidomide in Previously Untreated CLL/SLL

University of Wisconsin, Madison

Phase 2 Completed
36 enrolled 11 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphoid, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01116193 2017-09-14

RV-405 LAL

Institut de Cancérologie de la Loire

Phase 2 Completed
10 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphoid, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00609869 2015-09-17

Lenalidomide in Comb w/Rituximab for Pts w/CD5+/CD20+ Hem Malignancies Who Relapse/Progress After Rituximab

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Completed
29 enrolled 9 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphoid, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡